Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Altered DNA Methylation Profiles in SF3B1 Mutated CLL Patients.
Pacholewska A, Grimm C, Herling CD, Lienhard M, Königs A, Timmermann B, Altmüller J, Mücke O, Reinhardt HC, Plass C, Herwig R, Hallek M, Schweiger MR. Pacholewska A, et al. Among authors: reinhardt hc. Int J Mol Sci. 2021 Aug 28;22(17):9337. doi: 10.3390/ijms22179337. Int J Mol Sci. 2021. PMID: 34502260 Free PMC article.
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.
Herling CD, Klaumünzer M, Rocha CK, Altmüller J, Thiele H, Bahlo J, Kluth S, Crispatzu G, Herling M, Schiller J, Engelke A, Tausch E, Döhner H, Fischer K, Goede V, Nürnberg P, Reinhardt HC, Stilgenbauer S, Hallek M, Kreuzer KA. Herling CD, et al. Among authors: reinhardt hc. Blood. 2016 Jul 21;128(3):395-404. doi: 10.1182/blood-2016-01-691550. Epub 2016 May 25. Blood. 2016. PMID: 27226433 Free article. Clinical Trial.
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP. Thijssen R, et al. Among authors: reinhardt hc. Blood. 2016 Jul 28;128(4):574-83. doi: 10.1182/blood-2016-02-700328. Epub 2016 May 27. Blood. 2016. PMID: 27235137 Free article. Clinical Trial.
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.
Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M. Lohmann G, et al. Among authors: reinhardt hc. Leukemia. 2017 May;31(5):1177-1186. doi: 10.1038/leu.2016.294. Epub 2016 Oct 24. Leukemia. 2017. PMID: 27773933
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen PH, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, P Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Buettner R, Persigehl T, Reinhardt HC. Knittel G, et al. Among authors: reinhardt hc. Nat Commun. 2017 Jul 28;8(1):153. doi: 10.1038/s41467-017-00210-6. Nat Commun. 2017. PMID: 28751718 Free PMC article.
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M. Schrader A, et al. Among authors: reinhardt hc. Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6. Nat Commun. 2018. PMID: 29449575 Free PMC article.
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.
Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, Cartolano M, Oberbeck S, Mayer P, Berg V, Thomalla D, Kutsch N, Stiefelhagen M, Cramer P, Wendtner CM, Persigehl T, Saleh A, Altmüller J, Nürnberg P, Pallasch C, Achter V, Lang U, Eichhorst B, Castiglione R, Schäfer SC, Büttner R, Kreuzer KA, Reinhardt HC, Hallek M, Frenzel LP, Peifer M. Herling CD, et al. Among authors: reinhardt hc. Nat Commun. 2018 Feb 20;9(1):727. doi: 10.1038/s41467-018-03170-7. Nat Commun. 2018. PMID: 29463802 Free PMC article. Clinical Trial.
171 results